A Novel Drug Discovery Platform Targeted at Neurodegeneration and Cognitive impairments
Neurotrope is developing Bryostatin 1 for the treatment of Alzheimer’s disease along with the vastly under-served rare (Orphan) diseases, Fragile X Syndrome and Niemann-Pick Type C. Second generation PKC activators, such as the Bryologs are in the early phases of product development.
Our rich pipeline of product candidates demonstrates our ability to gain a leadership position in drug development for Alzheimer’s and other rare diseases diseases. In our short history, we have demonstrated an ability to progress multiple programs through development and into the clinic. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients.